Lung Cancer

Activating mutations in this class of oncogenes, specifically KRAS, have made a big step forward scientifically and clinically just in the last couple of years.

Recent advancements surrounding the development of biomarker- targeted therapies have revolutionized the treatment of lung cancer.

Patients who are part of an advocacy group may be better equipped to understand biomarker testing during a lung cancer diagnosis and feel more empowered.

Over the past 20 years, advancements in the lung cancer space have led to a drastic paradigm shift in how patients are now treated, ultimately leading to substantial improvements in survival and patient quality of life.

The FDA’s recent approval of Opdivo plus chemotherapy may be beneficial for some patients with non-small cell lung cancer, further highlighting the need for multidisciplinary care.

Anti-TIGIT immunotherapy drugs may improve quality of life and survival, while being well tolerated by patients.

The KRAS G12C gene mutation in non-small cell lung cancer has been deemed “undruggable,” but recent effective therapies have successfully targeted this mutation, leading to shrinking of tumors and longer survival.

As part of its Speaking Out video series, CURE spoke with Sarah Miretti Cassidy, director of external affairs at Cancer Hope Network, about the importance of support following a lung cancer diagnosis.

As part of its Speaking Out video series, CURE spoke with Sarah Miretti Cassidy, director of external affairs at Cancer Hope Network, about the psychosocial effects of a lung cancer diagnosis.

As part of its Speaking Out video series, CURE spoke with Sarah Miretti Cassidy, from Cancer Hope Network, about seeking support for patients who may be nearing end of life, as well as support for family and friends after a loved one has passed.

“It’s important for patients to be educated on (next-generation sequencing), because the more we know about a patient’s cancer, the better we can design a personalized treatment plan,” says an expert.

Tiragolumab plus Tecentriq and chemotherapy did not significantly improve progression-free survival and overall survival in patients with extensive-stage small-cell lung cancer.

The FDA’s decision follows a recommendation from a panel of experts that suggested the agency not approve sintilimab plus the chemotherapy pemetrexed and platinum-based chemotherapy for patients with non-squamous non-small cell lung cancer.

From Pfizer issuing a voluntary recall of three blood pressure drugs due to a high level of a cancer-causing chemical to “Today Show” co-ancho Hoda Kotb discussing her struggles with fertility after receiving a diagnosis of breast cancer, here’s what’s happening in the cancer space this week.

The FDA’s approval of the Opdivo plus platinum-doublet chemotherapy regimen marks the agency’s first greenlight, according to manufacturer Bristol Myers Squibb, of an immunotherapy-based treatment in the pre-surgical setting for non-small cell lung cancer.

From a “Jeopardy!” winner taking her wig off on the gameshow to childhood patients with cancer in Ukraine being bussed to neighboring countries to safely receive treatment, here’s what’s happening in the cancer space this week.

The number of people developing leptomeningeal disease is increasing for the same reason that diagnoses of brain metastases are on the rise: People are living longer, giving cancer more time to spread.

Better therapies are on the horizon for cancer that has spread to the brain, including a clinical trial that matches patients with treatments based on unique genetic changes in brain metastases.

The Food and Drug Administration plans to speed up its review of Opdivo in the pre-surgical setting for patients with non-small cell lung cancer.

From NBC4 meteorologist Bob Nunnally’s break for cancer treatments to Mary J. Blige’s Super Bowl commercial encouraging others to undergo cancer screenings, here’s what’s happening in the cancer landscape this week.

Two experts explain how early-stage non-small cell lung cancer treatment has changed in recent years, particularly in the adjuvant setting, and offer future perspectives in this space.

After the death of his wife, former NFL linebacker Chris Draft has been advocating for improvements for all patients with cancer — a mission that perfectly aligns with the recently relaunched Cancer Moonshot initiative.

Dr. Jessica Donington provides an overview of key ongoing clinical trials of systemic adjuvant therapy in early non-small cell lung cancer.

An expert surgeon explains the role patients have in adjuvant therapy selection for early non-small cell lung cancer.

Patients with lung cancer whose symptoms were managed by automated alerts to their care team through an electronic system after surgery had fewer post-surgical complications than patients who received standard care.

Dr. Martin Dietrich reviews some factors to consider when selecting an adjuvant therapy for early non-small cell lung cancer.

Jessica Donington, MD, MSCR, describes how she discusses adjuvant therapy with patients diagnosed with early non-small cell lung cancer.

Patients who limit alcohol intake during their cancer treatment may experience several health benefits, according to physicians from Tampa Bay Radiation Oncology.

Side effects from cancer treatment with immunotherapy, which may include vitiligo and certain rashes, may point to who will respond better to the treatment, although more research is needed to determine how much weight to put on these data.